BMS signs $475m deal with Dragonfly Therapeutics for IL-12 programme
The agreement between Bristol Myers Squibb and Dragonfly Therapeutics includes DF6002, an extended half-life IL12 cytokine, which is being studied as a treatment for advanced solid tumours in